Trial Profile
A Phase II Study of Ibrutinib in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2019
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2019).
- 31 Aug 2018 Biomarkers information updated
- 02 May 2018 Planned End Date changed from 1 Apr 2021 to 1 Jan 2022.